Skip to main content
. Author manuscript; available in PMC: 2016 Jul 14.
Published in final edited form as: Mol Cancer Ther. 2010 Dec 29;10(2):360–371. doi: 10.1158/1535-7163.MCT-10-0760

Figure 1. Chemical structure of CCT128930 and crystal structure of CCT128930 bound to a chimeric PKA-AKT protein.

Figure 1

A Chemical structure of CCT128930 (4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine)

B X-ray crystal structure of CCT128930 bound to PKA-AKT chimeric protein (PDB code 2V06; (12)). The inhibitor (amber) and key residues in the ATP-binding site (grey) are shown with hydrogen-bonding interactions indicated (dashed lines). The residue targeted by CCT128930 to give selective inhibition of AKT over PKA is highlighted (Met173 in PKA-AKT chimera, equivalent to Met282 in AKT) (12, 13).